(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/056020 A1

(51) International Patent Classification:
A61K 31/438 (2006.01) *A61K 31/519* (2006.01)
A61K 31/513 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/045391

(22) International Filing Date:
30 September 2022 (30.09.2022)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
63/250,883 30 September 2021 (30.09.2021) US

(71) Applicants: **NAVIRE PHARMA, INC.** [US/US]; 421 Kipling Street, Palo Alto, CA 94301 (US). **BRIDGEBIO SERVICES, INC.** [US/US]; 421 Kipling Street, Palo Alto, CA 94301 (US). **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 & Province Line Road, Princeton, NJ 08453 (US).

(72) Inventors: **BELTRAN, Pedro**; 421 Kipling Street, Palo Alto, CA 94301 (US). **DAMBKOWSKI, Carl**; 421 Kipling Street, Palo Alto, CA 94301 (US). **LIM, Justin**; 421 Kipling Street, Palo Alto, CA 94301 (US). **WADE, Anna**; 421 Kipling Street, Palo Alto, CA 94301 (US). **WALLACE, Eli**; 421 Kipling Street, Palo Alto, CA 94301 (US). **SUN, Yuting**; 421 Kipling Street, Palo Alto, CA 94301 (US). **KOHL, Nancy**; 421 Kipling Street, Palo Alto, CA 94301 (US). **MEYERS, Brooke**; 421 Kipling Street, Palo Alto, CA 94301 (US). **SINKEVICIUS, Kerstin**; 421 Kipling Street, Palo Alto, CA 94301 (US). **STICE, James**; 421 Kipling Street, Palo Alto, CA 94301 (US). **VAN VEENHUYZEN, David**; 421 Kipling Street, Palo Alto, CA 94301 (US). **WOOD, Lauren**; 421 Kipling Street, Pa-

(54) Title: COMBINATION THERAPY USING A PTPN11 INHIBITOR AND A KRAS G12C INHIBITOR



(I)




FIG. 8

(57) Abstract: The present disclosure provides a method of treating cancer in a subject. The method including administering to the subject: a) a therapeutically effective amount of a PTPN11 inhibitor; and b) a therapeutically effective amount of a KRAS G12C inhibitor, wherein the PTPN11 inhibitor is represent by formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, conformational isomer, tautomer, or a combination thereof, wherein the subscripts a and b, Y_1, Y_2, and R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, and R_{13} are as provided herein. In particular, the present disclosure provides a method of treating a solid tumor (e.g., an advanced non- small cell lung cancer) with a therapeutically effective amount of a compound of formula (10b) (i.e., 6-((35,45)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R_a)-(2,3-

[Continued on next page]

WO 2023/056020 A1

lo Alto, CA 94301 (US). **TWYMAN-SAINT VICTOR, Christina**; Route 206 & Province Line Road, Princeton, NJ 08453 (US). **DING, Lina**; 100 Binney Street, Cambridge, MA 02142 (US). **MORRIS, Erick**; 100 Binney Street, Cambridge, MA 02142 (US). **LIU, Yu**; 100 Binney Street, Cambridge, MA 02142 (US). **MEYER, Matthew**; 100 Binney Street, Cambridge, MA 02142 (US).

(74) **Agent: DONG, Yaohua**; Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

dichlorophenyl)-2,5-dimethylpyrimidin-4(3*H*)-one) in combination with a KRAS G12C inhibitor in a subject, wherein the subject has one or more mutations in KRAS, such as KRAS G12C.